chronic hypertension in pregnancy
HTN before conception or <20 wk. Treat at ≥140/90, target DBP 85 (CHIPS achieved SBP ~133); <130/80 if pregestational diabetes . Labetalol, nifedipine XL, methyldopa first-line. ACEi/ARB stop at positive pregnancy test. Baseline uPCR + Cr early — without it, superimposed preeclampsia can’t be called later. Aspirin from 12–16 wk.
treatment thresholds and targets
- Start/continue therapy at average ≥140/90 — don’t wait for severe range (CHAP (2022))
- Target DBP 85 (CHIPS (2015)); in practice SBP 130–140
- Pregestational DM: <130/80
- BP falls ~10% in first/second trimester → some can reduce or stop therapy; re-escalate from ~20 wk
- 2025 Canadian primary-care HTN guideline explicitly excludes pregnancy — use SOGC
oral agents
SOGC 2022 titration (start monotherapy; add a second class before maxing if needed, up to 3 drugs):
| drug | low | medium | high | max | caution |
|---|---|---|---|---|---|
| labetalol | 100 mg TID–QID | 200 mg TID–QID | 300 mg TID–QID | 1200 mg/d | contraindicated in poorly controlled asthma; neonatal bradycardia/hypoglycaemia → newborn glucose screen |
| nifedipine XL | 30 mg daily | 30 mg BID or 60 mg daily | 30 mg AM + 60 mg PM | 120 mg/d | contraindicated in aortic stenosis; ensure XL |
| methyldopa | 250 mg TID–QID | 500 mg TID–QID | 750 mg TID | 2500 mg/d | depression, sedation, LFT rise |
- Other first-line β-blockers: metoprolol, propranolol, acebutolol, pindolol
- Second-line: clonidine, hydralazine, thiazides (continue if pre-existing); amlodipine — insufficient data
- Starting doses are higher than non-pregnant (faster clearance)
- ACEi/ARB, direct renin inhibitors — fetopathy (renal agenesis/dysgenesis, oligohydramnios, pulmonary hypoplasia, skull hypoplasia), mostly T2–T3 → switch pre-conception or at positive test; proteinuric CKD/diabetic nephropathy may continue until positive test
- atenolol — FGR (and neonatal bradycardia via breast milk)
- spironolactone — antiandrogenic; limited data
- prazosin — limited data, avoid peripartum
- Postpartum/breastfeeding (SOGC): labetalol, methyldopa, nifedipine, enalapril, captopril — resume ACEi for proteinuria postpartum
baseline workup (first visit)
- CBC, Cr, electrolytes, AST/ALT, uPCR (or uACR), urinalysis
- ECG if long-standing/severe; echo if LVH or symptoms
- Secondary HTN screen if young, resistant, or suggestive features (aldosteronism, renal artery stenosis, phaeochromocytoma, CKD) — workup limited in pregnancy, prioritise pre-conception
- Aspirin 81–162 mg qhs from 12–16 wk to 36 wk
- Growth ultrasound surveillance (FGR, SGA)
- Delivery: expectant to 37 wk if well; offer induction 38⁺⁰–39⁺⁶, advise from 40⁺⁰ wk
superimposed preeclampsia
Diagnose when, on chronic HTN:
- new/worsening proteinuria vs documented baseline, or
- any adverse condition (symptoms, plt <100, ↑AST/ALT, ↑Cr, foetal growth restriction), or
- resistant HTN (needs ≥3 agents) after 20 wk
Management → hypertensive disorders of pregnancy. Higher perinatal mortality than preeclampsia arising from gestational HTN.
27 wk, nifedipine XL, BP 154/96, uPCR 72 (baseline 12), Cr 83, plt 145. This is superimposed preeclampsia until proven otherwise → admit/urgent obstetric review, symptoms, labs, foetal assessment. Cr 83 µmol/L is already abnormal in pregnancy (see physiology and lab interpretation in pregnancy).
complications
- Maternal: superimposed preeclampsia (~20–25%), abruption, stroke, AKI, HF
- Foetal: FGR/SGA, preterm birth (often iatrogenic), stillbirth
evidence
- CHAP (2022) — n=2408, mild CHTN <23 wk; treat to <140/90 vs only if ≥160/105: composite (severe preeclampsia, PTB <35 wk, abruption, foetal/neonatal death) 30.2% vs 37.0%; no ↑ SGA
- CHIPS (2015) — n=987; DBP 85 vs 100: no perinatal difference; less-tight → more severe maternal HTN
Prepared 2026-10-18. Not yet verified — check every number against the sources.